SCHEMBL5547166

SCHEMBL5547166

CCN(CC)C1CCN(c2ccc([O])cc2)CC1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.39
USP2 O75604 1/20 0.38
LSS P48449 1/20 0.37
ACKR3 P25106 1/20 0.37
L3MBTL3 Q96JM7 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CBX7 O95931 1/20 0.36
CDYL2 Q8N8U2 1/20 0.36
CDYL Q9Y232 1/20 0.36
MCHR1 Q99705 1/20 0.36
CDK4 P11802 7/20 0.36
CCND1 P24385 2/20 0.36
CDK2 P24941 2/20 0.36
CDK6 Q00534 1/20 0.35
MAPT P10636 1/20 0.35
CHIT1 Q13231 2/20 0.34
CHIA Q9BZP6 2/20 0.34
RORC P51449 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5542760 0.87 DRD3 (0.44)
SCHEMBL8728925 0.85 ADRB1 (0.46) SMN1; SMN2USP2L3MBTL3L3MBTL1CDK4
SCHEMBL8728922 0.83 L3MBTL3 (0.37) SMN1; SMN2USP2LSSACKR3L3MBTL3
SCHEMBL520505 0.83 MAPT (0.53) SMN1; SMN2USP2L3MBTL3L3MBTL1CDK4
SCHEMBL5547171 0.83 KDM4E (0.45) SMN1; SMN2USP2CBX7CDYL2CDYL
SCHEMBL27995386 0.83 CHRNA7 (0.50) SMN1; SMN2L3MBTL3L3MBTL1
SCHEMBL7303320 0.81 MAPT (0.51) SMN1; SMN2USP2MCHR1MAPT
SCHEMBL4696324 0.81 ACKR3 (0.35) SMN1; SMN2ACKR3L3MBTL3L3MBTL1CBX7
SCHEMBL5539924 0.81 L3MBTL3 (0.46) USP2LSSL3MBTL3L3MBTL1MCHR1
Hydrochloric Acid SCHEMBL7289172 0.79 MAPT (0.56) SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 SMN1; SMN2 3985/4885USP2 3074/4885LSS 2164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.